Assessing the occurrence of hypertension in patients receiving calcitonin gene-related peptide monoclonal antibodies for episodic and chronic migraine: a systematic review and meta-analysis
Meiqi Di, Lingling Hu, Shuhua Gui, Chaosheng Li, Likun Han · 2024
Read Assessing the occurrence of hypertension in patients receiving calcitonin gene-related peptide monoclonal antibodies for episodic and chronic migraine: a systematic review and meta-analysis by Meiqi Di, Lingling Hu, Shuhua Gui, Chaosheng Li, Likun Han (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11810671.txt.
Description
Meiqi Di and co-authors review trial evidence in a 2024 paper on migraine drugs and high blood pressure. The drugs target a peptide called CGRP and are used for both episodic and chronic migraine. The team searched three databases through April 2024 for randomized trials in adults.
They compared these drugs with placebo or other treatments and tracked how often high blood pressure occurred. Secondary outcomes were also assessed. For patients and doctors weighing a newer migraine option, the combined evidence helps judge whether blood pressure is a risk that needs watching during treatment.
Catalog record
| CREATOR | Meiqi Di, Lingling Hu, Shuhua Gui, Chaosheng Li, Likun Han |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |